Objective: To measure the intrapharyngeal pressure (IPP) generated by high-flow nasal cannula (HFNC) at varying flow rates up to 5 l min À1 .
Introduction
Continuous positive airway pressure (CPAP) is becoming a gold-standard technology to treat respiratory distress of the newborn and reduce the need for intubation. [1] [2] [3] However, nasal CPAP provided by currently available devices (Infant-flow, INCA, and so on) has some well-known draw-backs such as septal erosion and technical problems including the difficulty keeping the device on the infant's nose and maintaining an effective seal. 4, 5 For these reasons, other methods to deliver CPAP are being investigated.
High-flow nasal cannula (HFNC) is a commonly used technology in many newborn intensive care units. Some studies have shown HFNC may generate clinically significant CPAP without the complications of septal erosion and difficulties of maintaining device position and thus maintains the efficacy. 6, 7 The flows needed to generate significant and sufficient CPAP are unknown but HFNC use is not without controversy. Before HFNC was coupled with humidification technology, nasal cannula (NC) flow was limited to a maximum of 2 to 3 l min À1 due to extreme discomfort, desiccation of secretions and damage to nasal passages. The warmth and humidification allow high flows to be comfortably tolerated by the patient. 7, 8 Sreenan et al. 6 showed that NC can deliver positive distending pressure (PDP) to premature neonates if the flow is increased up to 2.5 l min
À1
. The pressure generated is determined by primarily the structure of the cannula, gas flow and the anatomy of the infant's airway. 6 As most factors are not variable, the PDP produced is mainly proportional to the gas flow rate. 6, 9, 10 However, the amount of CPAP generated at higher flows of 2 to 5 l min
is not well-studied. Despite the unknown CPAP generated, the application of HFNC seems to have been rapidly accepted because of its simplicity, ease of use, apparent effectiveness and the introduction of a device that permits adequate heating and humidification. 7, 8, 11, 12 Our study intends to corroborate and extend the preliminary work done to assess CPAP generated on HFNC by studying intrapharyngeal pressure (IPP) generated in infants at flows of 1 to 5 l min À1 . The primary aim of our study was to determine the amount of CPAP as measured by IPP, if any, that HFNC generates. A secondary aim was to make a correlation between HFNC flow rate and the amount of CPAP generated, using NCPAP as a control.
Methods
This was an observational study conducted at St Louis Children's Hospital (SLCH) Neonatal Intensive Care Unit (NICU) from March 2006 through March 2007 on a convenience sample of stable term and preterm infants who were being treated either with NCPAP or with HFNC. Exclusion criteria included patients who were clinically unstable or had airway anomalies. The study was approved by the Human Research Protection Office at Washington University in St Louis, and an informed parental consent was obtained. Each participant was observed for at least one study session, lasting approximately 30 min.
Basic health information and vital signs were obtained prior to the study session. Infant vital signs, oxygen saturation and work of breathing were continuously monitored. A Viasys 5 French Tracheal Catheter (PN 10635, Viasys Healthcare, Yorba Linda, CA, USA) was gently introduced to the posterior pharynx through the infant's nares or mouth. Depth of insertion was estimated by measuring the distance between the corner of the nare and the ear lobe. The catheter was connected to Airlife oxygen tubing, Viasys Tracheal Catheter Extension Tube (PN 50000-40040, Airlife Medical LLC, Auburndale, FL, USA) and a pressure-measuring device (Viasys avea ventilator), which continuously recorded the IPP. The NCPAP device used for the study varied depending on initial patient CPAP device. The Viasys Infant Flow CPAP System was the primary device used for this study. HFNC was delivered via Fischer & Paykel (Fisher & Paykel Healthcare Inc. Irvine, CA, USA) humidification system and Salter brand infant nasal cannula. All the infants had the 'infant size' prongs from Salter.
We monitored the IPP during a period of fixed flow and compared the IPP recordings at variable flow rates of HFNC. IPPs were recorded for 2 to 3 min or until airway pressure and infant were stabilized at each level NCPAP of 2, 4 and 6 cm H 2 O and HFNC of 1, 2, 3, 4 and 5 l min À1 average pressure waves were documented over the 2 to 3 min observation period at each NCPAP and HFNC level and a single value was recorded. Infants' mouths were kept closed by gentle chin support and/or pacifier placement. At study completion participants were returned to their original devices (NCPAP or HFNC) and settings.
All data were entered into a database and analyzed with the SPSS system for personal computers (SPSS Systems (version 11.5, SPSS Inc., Chicago, IL, USA). A descriptive analysis was performed to calculate the mean and standard deviations of the IPP generated on CPAP at the pressures of 2, 4 and 6 cm H 2 O and HFNC at the varying flow rates of 1, 2, 3, 4 and 5 l min À1 . A regression analysis was performed to assess the correlation between the IPP generated on the HFNC and NCPAP. Paired analyses (t-tests) was then used to compare IPP between the varying flow rates on HFNC to determine if there was statistical significance between the different IPPs measured between each incremental increase in flow rate. Regression was performed to determine if weight was a significant predictive variable. A value of P<0.05 was considered statistically significant.
Results
We studied 14 infants (Table 1) , 6 of whom were studied on both CPAP and HFNC. Two infants only had IPP measured on CPAP, and six infants had only IPP measured on HFNC. The measured IPP on NCPAP correlated with the pressure measured by the CPAP device, validating our method of measurement and correlating IPP with CPAP (Figure 1) .
Except for one patient, HFNC consistently generated a significant amount of CPAP: the average IPP (cm of H 2 O) for flow rates of 1, 2, 3, 4 and 5 l min À1 was 1.7 þ 0.3, 1.7±0.2, 2.6±0.3, 3.8±0.4 and 4.8±0.5 respectively (Figure 2) . In one patient, flows at 1 to 5 LPM generated an IPP of p2 cm H 2 O. We did not find a correlation between the size of the baby and the IPP generated at each flow rate, but were not powered to do so (P ¼ 0.707). 
Discussion
The novelty of this study is the ease of measuring IPP and its near 1:1 correlation with NCPAP as measured by a pressure transducer in the proximal airway. IPP measurement is less invasive and cumbersome than measuring esophageal pressure, which historically has been used to assess respiratory mechanics in infants. 9,13 -15 Sola and colleagues suggested that mean airway pressure measured at the proximal airway is a more valid reflection of peak inspiratory pressure. 15 In summary, this study describes a straightforward way to measure or 'spot-test' the amount of IPP generated by HFNC on individual patients.
Also noteworthy is that airflow does not seem to generate a clinically significant CPAP until 3 l min À1 above which the IPP increases linearly with flow. Because we did not increase the flow greater than 5 l min
À1
, we do not know whether the pressure would continue to increase or plateau. The fact that the IPP does increase up to 5 l min À1 suggests caution when using higher flows than this. Sreenan et al. while evaluating the efficacy of HFNC in 40 preterm infants in the prevention of apnea of prematurity also measured end expiratory esophageal pressure on CPAP and NC up to flow rates of 2.5 l min À1 . Sreenan's study found weight to be a variable with respect to the esophageal pressure measured. 7 This may be the case at lower flow rates, but however, we demonstrated that flow rates of less than 3 l min À1 are on the non-linear portion of the curve (Figure 2 ). This could explain the difference in end expiratory pressure measured by Sreenan et al. More importantly esophageal pressure measurements often underestimate the actual airway pressure measured and thus Sreenan et al.'s values might not have been a direct reflection of IPP. 14, 16, 17 Concerns have been raised regarding the wide acceptance and application of HFNP. A major concern was the inadequate research of its safety. 11 The new safety of HFNP relies on the improved technology that provides warmth and humidification. With proper warmth and humidification, the infants tolerate higher flows of HFNC without complications from inspissated secretions, desiccation of the nose and infection. 7, 8 As with CPAP, meticulous oral and nasal hygiene are required to maintain patent nares and airway, and thus ensure success and safety of this respiratory device. Hygiene can be standardized in nurseries by providing education and guidelines for nurses and respiratory therapists. Another concern was the inability of current delivery systems to prevent excessive pressure delivery to the infants' airways. 11 We do know from other studies that the pressures might be higher upstream as documented by Locke et al. 9 in infants studied at <28 days of age. Anecdotally, our NICU has used HFNC up to 8 l min À1 over the past three years with no recorded adverse events (over 550 infants with varying diagnoses and gestational ages), but we do not have any measurements of IPP on these higher flow rates.
Finally, another criticism was the lack of reliability of the CPAP generated by HFNC because of the dynamic variables affecting the pressure generated in the airway. With meticulous oral and nasal hygiene and attention to the position of the mouth (open or closed) these variables can be managed. Also with this technique, the IPP being generated is easily measured within a few minutes, and there is very little disruption in care. The data indicated a wide range of values but, however, this was largely secondary to two subjects; one with very high IPP measurements and another with very low. This was somewhat linked to the size of these infants as the one with low IPP measurements was 2100 g and the other with higher IPPs was only 800 g. Otherwise, the majority of the data did cluster well. Such variability in the IPP generated by HFNC in some individuals is a cause of concern for the clinical application of HFNC. It becomes critical to develop an inline manometer that is able to measure pressure generated and provide a 'pop-off' mechanism so as not to exceed a set pressure. This differential effect could be the cause of the controversial clinical outcomes; Campbell et al. 18 found HFNC significantly worse at maintaining extubation. However, Shoemaker et al. 19 found improved extubation success rates with HFNC (up to 8 l min À1 ) and Saslow et al. 10 did not find any increased work of breathing between NCPAP and HFNC at flows 3 to 5 l min À1 . The clinical role of HFNC is still evolving.
The limitation of our study was the limited duration of the monitoring. However, data could easily be collected to generate more evidence in support of HNFC efficacy, role and safety in a larger study. This larger study then could identify which infants will have IPP much higher or lower than anticipated and how that relates to weight/size. Also, a study that monitors IPP for longer periods may provide an insight into the variability of IPP delivered in the same infant over time. This longer study duration could help establish the relationship of IPP generated to states of mouth opening, straining or even progression of the lung pathology.
In conclusion, HFNC can deliver significant IPPs at flows X3 l min
À1 . There appears to be a linear relationship between airflow and IPP generated at X3 l min À1 . A larger trial could extend the preliminary data accrued to further investigate the variability of airway pressure generated and its impact on patient's safety.
